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BRIEF REPORT
Effect of Ambrisentan Treatment on Exercise-Induced Pulmonary Hypertension
in Systemic Sclerosis: A Prospective Single-Center, Open-Label Pilot Study
Rajeev Saggar,1 D. Khanna,2 S. Shapiro,3 D. E. Furst,3 P. Maranian,3 P. Clements,3 F. Abtin,3 Shiv Dua,4
J. Belperio,3 and Rajan Saggar3
Objective. Exercise-induced pulmonary hyperten-
sion (ePH) may represent an early, clinically relevant
phase in the spectrum of pulmonary vascular disease.
The purpose of this pilot study was to describe the
changes in hemodynamics and exercise capacity in
patients with systemic sclerosis (SSc) spectrum–
associated ePH treated with open-label daily ambrisen-
tan.
Methods. Patients were treated with ambrisentan,
5 mg or 10 mg once daily, for 24 weeks. At baseline and
24 weeks, patients with SSc spectrum disorders exer-
cised in a supine position, on a lower extremity cycle
ergometer. All patients had normal hemodynamics at
rest. We defined baseline ePH as a mean pulmonary
artery pressure of >30 mm Hg with maximum exercise
and a transpulmonary gradient (TPG) of >15 mm Hg.
The primary end point was change in pulmonary vas-
cular resistance (PVR) with exercise. Secondary end
points included an improvement from baseline in
6-minute walking distance, health-related quality of life
assessments, and cardiopulmonary hemodynamics.
Results. Of the 12 enrolled patients, 11 completed
the study. At 24 weeks there were improvements in mean
exercise PVR (85.8 dynes  second/cm5; P  0.003) and
mean distance covered during 6-minute walk (44.5
meters; P  0.0007). Improvements were also observed
in mean exercise cardiac output (1.4 liters/minute; P 
0.006), mean pulmonary artery pressure (4.1 mm Hg;
P  0.02), and total pulmonary resistance (93.0
dynes  seconds/cm5; P  0.0008). Three patients
developed resting pulmonary arterial hypertension dur-
ing the 24 weeks.
Conclusion. Exercise hemodynamics and exercise
capacity in patients with SSc spectrum–associated ePH
improved over 24 weeks with exposure to ambrisentan.
Placebo-controlled studies are needed to confirm
whether this is a drug-related effect and to determine
optimal therapeutic regimens for patients with ePH.
Despite fewer severe hemodynamic abnormali-
ties, patients with systemic sclerosis (SSc) pulmonary
arterial hypertension (PAH) tend to have a poorer
prognosis compared to those with other types of associ-
ated PAH or idiopathic PAH (1). Survival is related, in
part, to the degree of hemodynamic compromise, with
key variables, including resting pulmonary vascular re-
sistance (PVR), stroke volume index, and pulmonary
arterial capacitance, all strongly associated with mortal-
ity (2). In addition, data from a large registry in the UK
show that one-fifth of SSc patients with exercise-induced
pulmonary hypertension (PH) developed resting PAH
after 2.3 years (3).
We recently reported on 4 potential hemody-
namic phenotypes of SSc spectrum disorders that
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emerge in patients exercising with catheterization of the
right side of the heart, including normal, exercise-
induced pulmonary venous hypertension (ePVH), exer-
cise out of proportion pulmonary hypertension (eoPH),
and exercise-induced pulmonary hypertension (ePH)
(4). Our findings and those of others suggest that SSc
patients with a borderline resting mean pulmonary
artery pressure (mPAP) of 21–24 mm Hg and/or a PVR
of 160 dynes  seconds/cm5 at baseline are at higher
risk of developing progressive pulmonary vascular dis-
ease (4,5). A hemodynamic evaluation of SSc-associated
PH patients during exercise may allow for earlier diag-
nosis, initiation of appropriate therapy, and perhaps, a
more favorable outcome (6). In this 24-week uncon-
trolled, open-label study, we assessed the effects of
open-label ambrisentan on cardiopulmonary hemody-
namics during exercise, exercise capacity, and the safety
and tolerability of ambrisentan in patients with SSc-
associated ePH.
PATIENTS AND METHODS
This prospective study involved 12 patients with SSc
spectrum disorders who underwent exercise with catheteriza-
tion of the right side of the heart at a single university hospital.
This data collection was approved by the University of Cali-
fornia, Los Angeles Institutional Review Board.
We identified patients with an SSc spectrum disease
(either limited cutaneous SSc, diffuse cutaneous SSc, or an
overlap syndrome), based on the American College of Rheu-
matology classification criteria (7). Disease duration was de-
fined as the time since the first non–Raynaud’s phenomenon
symptom attributable to SSc. Patients of either sex, without
limitations on disease duration, were eligible for the study.
Based on prior published recommendations, patients
underwent right-sided heart catheterization if they had dys-
pnea and at least 1 of the following: a resting Doppler
echocardiography–estimated right ventricular systolic pressure
of 30 mm Hg (8), a 15% decline in diffusing capacity for
carbon monoxide (DLco) (% of predicted) during the preced-
ing 2 years, a DLCO of 60%, or a forced vital capacity
(FVC):DLCO ratio of 1.4% predicted (9,10). Patients with
moderate-to-severe pulmonary fibrosis were included in the
analysis. The degree of fibrosis on high-resolution computed
tomography (CT) of the chest was scored by a thoracic
radiologist (FA), who was blinded with regard to clinical and
hemodynamic information, using a grading system based on a
modified Likert scale (0  absent, 1  1–5%, 2  6–25%, 3 
26–50%, 4  51–75%, 5  76–100%) (11). Using results of
Doppler echocardiography, we excluded patients who had
evidence of significant resting systolic dysfunction (ejection
fraction 50%) and/or diastolic dysfunction (more than mild)
of the left side of the heart.
Study protocol. The majority of patients were initially
started on 10 mg of ambrisentan daily; however, titration was
allowed based on physician discretion. The drug was provided
by Gilead Sciences for the duration of the study. Safety
laboratory testing was performed on a monthly basis, including
blood tests for determination of liver and renal function and
complete blood cell counts. Due to a high incidence of edema
(especially lower extremity) that was successfully managed by
daily or intermittent administration of diuretics, 2 patients
were treated with 5 mg of ambrisentan daily for the first
month, after which the dosage was increased to 10 mg daily.
Daily ambrisentan was continued for 24 weeks. The patients
were asked to return 4 weeks after discontinuing the drug, for
a safety assessment.
Health-related quality of life (HRQOL) measures.
HRQOL was assessed using the Short Form 36 (SF-36) health
survey, version 2 (12), the Health Assessment Questionnaire
(HAQ) disability index (DI) (13), and the Cambridge Pulmonary
Hypertension Outcome Review (CAMPHOR) index (14).
Definition of PH. PH was defined as a resting mPAP of
25 mm Hg with right-sided heart catheterization; PAH was
defined as PH in addition to pulmonary capillary wedge
pressure (PCWP) of 15 mm Hg (15). A hemodynamic
evaluation was performed during maximal exercise in patients
without resting PH. We defined ePH as an mPAP of 30 mm
Hg, PCWP of 18 mm Hg (16), and a transpulmonary
gradient (TPG) of 15 mm Hg (17), where TPG  mPAP –
PCWP. We defined ePVH as an mPAP of 30 mm Hg, PCWP
of 18 mm Hg, and a TPG of 15 mm Hg. We defined eoPH
as an mPAP of 30 mm Hg, PCWP of 18 mm Hg, and a TPG
of 15 mm Hg (4). Our hypothesis was that SSc patients with
normal exercise physiology and ePVH have a different patho-
physiology compared to patients with pulmonary vascular
disease (ePH and eoPH). Since patients with ePH and eoPH
are otherwise hemodynamically indistinguishable during exer-
cise, they may be at risk of developing progressive pulmonary
vascular disease and were included in this analysis (4), while
the normal and ePVH groups were excluded.
Resting and exercise right-sided heart catheterization
protocol. Hemodynamic evaluation was performed with pa-
tients at rest and during exercise. Exercise was performed with
the patient in a supine position, using a lower extremity cycle
ergometer according to our standard protocol as previously
described (4).
Statistical analysis. Continuous variables are reported
as the mean  SD, while categorical variables are reported as
the percentage of patients. The statistical significance of
changes in scores from baseline was assessed using either
Student’s paired t-test or Wilcoxon’s rank sum test depending
on the distributional properties of each variable.
RESULTS
Patient characteristics. Twelve patients with SSc
spectrum disorders met inclusion criteria and agreed to
participate in the study. At baseline, the mean  SD
distance covered during the 6-minute walk test was
404.7  75.4 meters. The majority of patients were
women (91.6%) and white (33.3%) or African American
(33.3%); the mean  SD age was 47.6  19.4 years
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(Table 1). Eight patients (66.7%) had limited cutaneous
SSc, 3 (25%) had diffuse cutaneous SSc, and 1 (8.3%)
had an overlap syndrome. The mean FVC was 69.8%,
the mean DLco was 58.5%, and the mean FVC:DLco
ratio was 1.24. Two patients had an FVC of 60%, and
their fibrosis scores on CT chest scans were grades 3 and
4, respectively. Patients had mild functional disability
(mean HAQ DI 0.51), and their SF-36 physical compo-
nent summary score was 1.3 SD below the average for
the US general population. CAMPHOR function scores
(mean 8.9) were somewhat better than those found in a
US population study (14), whereas symptom scores
(mean 10.5) as assessed by CAMPHOR were somewhat
worse.
Resting hemodynamics. Resting cardiopulmo-
nary hemodynamics at baseline and at week 24 are
reported in Table 2. No significant changes in mPAP,
PCWP, pulmonary artery O2 saturation (Svo2), PVR,
total pulmonary resistance (TPR), and heart rate were
seen between baseline and study end. A significant
improvement in stroke volume index and stroke volume
was seen at week 24 compared to baseline. Three
patients had developed resting PAH (15) (mPAP of
25 mm Hg at week 24). Of those patients, 2 had an
increase in resting PVR and TPR and a decline in
resting stroke volume, stroke volume index, and pulmo-
nary arterial capacitance (stroke volume/pulse pressure
[SV/PP]). The remaining patient exhibited a decline in
resting PVR and TPR, and an increase in resting stroke
volume, stroke volume index, and SV/PP.
Exercise hemodynamics. Cardiopulmonary he-
modynamics during exercise significantly improved from
baseline to week 24 (Table 2). During exercise, mean 
SD values decreased as follows: mPAP 41.5 to 37.4 (P 
0.02), PVR 247.1 to 161.3 (P  0.003), TPR 405.7 to
312.7 (P  0.0008) (Table 2). Improvement in cardiac
output, stroke volume, and stroke volume index was also
seen. No change in PCWP or SvO2 was observed. Inter-
estingly, a significant reduction in peak heart rate was
seen at week 24 compared to baseline (mean 131.5
versus 119.2; P  0.006).
Exercise capacity. After 24 weeks, 6-minute
walking distance significantly improved, by a mean  SD
of 44.5  10.3 meters. In 1 patient, who developed




(n  11) P
Resting, mean  SD
mPAP, mm Hg 20.9  2.9 22.2  5.8 0.65
CO, liters/minute 4.8  0.9 5.9  0.7 0.01
PCWP, mm Hg 11.3  3.5 11.9  2.3 0.58
SvO2, % 71.1  4.1 71.4  6.1 0.58
PVR, dynes  seconds/cm5 169.1  67.7 138.9  65.4 0.12
TPR, dynes  seconds/cm5 358.7  81.9 298.9  81.6 0.12
HR, beats per minute 81.1  17.2 78.8  14.9 0.52
SV, ml 60.2  9.9 78.4  16.0 0.003
SVI, ml/m2 33.7  5.6 43.5  10.7 0.006
Exercise, mean  SD
mPAP, mm Hg 41.5  5.3 37.4  8.3 0.02
CO, liters/minute 8.4  1.6 9.8  2.2 0.006
PCWP, mm Hg 16.5  5.2 17.8  3.5 0.88
SvO2, % 51.2  8.0 51.4  5.6 0.83
PVR, dynes  seconds/cm5 247.1  69.1 161.3  66.7 0.003
TPR, dynes  seconds/cm5 405.7  73.8 312.7  82.9 0.0008
HR, beats per minute 131.5  19.9 119.2  18.7 0.006
SV, ml 62.7  13.4 80.7  17.3 0.002
SVI, ml/m2 35.0  7.4 44.5  9.3 0.002
* mPAP  mean pulmonary artery pressure; CO  cardiac output;
PCWP  pulmonary capillary wedge pressure; SvO2  pulmonary
artery O2 saturation; PVR  pulmonary vascular resistance; TPR 
total pulmonary vascular resistance; HR  heart rate; SV  stroke
volume; SVI  stroke volume index.
Table 1. Baseline characteristics of the 12 study patients with SSc
spectrum disorders*
Age, years 47.6  19.4
Women, no. (%) 11 (91.6)
Race, no. (%)
White 4 (33.3)
African American 4 (33.3)
Asian 1 (8.3)
Hispanic 3 (25)




RP duration, years 12.3  9.4
Non-RP duration, years 8.0  4.1
WHO functional class II, no. (%) 12 (100)
FVC, % predicted 69.8  19.4
DLCO, % predicted 58.5  21.1
FVC:DLCO 1.24  0.26
Pulmonary fibrosis (HRCT), no. (%)
Grade 0 2 (16.6)
Grade 1 7 (31.8)
Grade 2 2 (16.6)
Grade 3 1 (8.3)
Grade 4 0 (0)
LVEF on echocardiography, % 55.8  4.7
Diastolic dysfunction, no. (%) 0 (0%)
Estimated RVSP, mm Hg 32.1  5.1
RV dilation, no. (%)
None 5 (41.6)
Mild 7 (58.3)
Pericardial effusion, no. (%) 0 (0)
CT fibrosis score 1.8  1.1
* Except where indicated otherwise, values are the mean  SD. SSc 
systemic sclerosis; RP  Raynaud’s phenomenon; WHO  World
Health Organization; FVC  forced vital capacity; DLCO  diffusing
capacity for carbon monoxide; HRCT  high-resolution computed
tomography; LVEF  left ventricular ejection fraction; RVSP  right
ventricular systolic pressure; RV  right ventricle.
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resting PH, exercise capacity declined by 37 meters. In 2
other patients, who also developed resting PH, the
6-minute walking distance improved by 53 meters. Eight
of 11 patients (72.7%) had a 10% improvement in
distance covered during the 6-minute walking test at 24
weeks compared to baseline. In the 6 patients who
discontinued ambrisentan after study completion at
week 24, distance covered during a 6-minute walking test
on week 28 declined by 20.5  30.5 meters from week 24
(data not shown). World Health Organization (WHO)
functional class was maintained through 6 months in the
majority of the group. One patient improved and 1
patient worsened by 1 functional class.
HRQOL assessments. Improvements in the re-
sults obtained with the 3 HRQOL instruments were not
significant (data not shown). The improvement in the
SF-36 physical component summary score (11.7 SD) was
greater than the minimally important difference. The
change in SF-36 mental component summary score and
HAQ DI did not reach minimally important difference
estimates.
Patients with an FVC of >60% versus those with
an FVC of <60%. Two patients (16.6%) had an FVC of
60%, while 10 (83.3%) had an FVC of 60%. Patients
with an FVC of 60% had a fibrosis score of 3 on CT
scan. There were significant differences between those
with an FVC of 60% and those with an FVC of 60%
in mean resting PVR (240.3 dynes  seconds/cm5 versus
116.4 dynes  seconds/cm5, respectively) and resting
TPR (420.3 dynes  seconds/cm5 versus 271.9 dynes 
seconds/cm5, respectively). There were no differences in
the hemodynamic parameters during exercise, including
mean PVR, TPR, cardiac output, mPAP, and maximum
heart rate.
Exercise out of proportion PH versus exercise-
induced PH. Three patients met criteria for eoPH; the
remainder were classified as having ePH. There were no
significant differences between these 2 groups in regard
to exercise hemodynamics, HRQOL, exercise capacity,
and adverse events.
Adverse events. Adverse events were common in
this 24-week, open-label trial (Table 3). Common ad-
verse events included lower extremity edema, nasal
congestion, and upper respiratory symptoms. One pa-
tient developed intractable lower extremity edema and
subsequently withdrew from the study at week 4; her
edema resolved thereafter. Nasal congestion in conjunc-
tion with upper respiratory symptoms was common
(41.6%) and usually self-limited. None of the patients
developed serum aminotransferase concentrations 3
times the upper limit of normal. One patient developed
alanine aminotransferase levels that were 2 times the
upper limit of normal; however, levels normalized on
repeat analysis without dose adjustment.
One patient was diagnosed as having nonmuci-
nous bronchoalveolar carcinoma after completion of the
study, which was determined not to be related to the
study drug. After a successful lobectomy, the patient is
doing well 2 years later. Less common adverse events
included constipation, body pain, and headaches. Numb-
ness and rash at the catheter insertion site after cathe-
terization of the right side of the heart occurred in 2
patients, without further sequelae.
DISCUSSION
Exercise-induced PH in patients with SSc may be
an abnormal hemodynamic response and part of a
continuum from normal hemodynamics to resting PH.
We previously reported that patients diagnosed as hav-
ing ePH or eoPH may be at risk of developing progres-
sive pulmonary vascular disease (4), and as such, we
included these patients in this study.
To our knowledge, this is the first open-label
pilot study of the clinical efficacy and safety of an
endothelin receptor antagonist for the treatment of
patients with SSc spectrum–associated ePH. Our results
suggest that long-term oral administration of ambrisen-
tan may be associated with significant improvement in
cardiopulmonary hemodynamics during exercise and
exercise capacity (6-minute walking distance) in these
patients. These improvements included a significant
decrease in PVR, TPR, and mPAP during exercise.
Additional improvements in cardiac output, stroke vol-
ume, and stroke volume index were seen.
Table 3. Adverse events during ambrisentan treatment*
Upper respiratory symptoms 2
Nasal congestion 5
Severe constipation 1
Severe joint and body pain 1






Increased fecal incontinence 1
Pulled back muscle 1
* Values are the number of events; in some patients, 1 adverse event
occurred.
† Results on liver function tests (LFT) were elevated to 3 times the
upper limit of normal.
‡ One patient discontinued treatment after 4 weeks.
§ Swollen eyes and itching skin.
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In SSc patients with PAH, PVR, stroke volume
index, and pulmonary arterial capacitance (SV/PP) are
strong predictors of mortality (2). However, there is a
paucity of data regarding longitudinal followup in pa-
tients with ePH; as such, predictors of progression and
survival have not been determined. Condliffe et al
reported survival in 42 SSc patients with ePH, of whom
19% progressed to having resting PAH within 2.3 years;
of those, 5 died secondary to complications of right
ventricular dysfunction (3). Tolle et al recently described
exercise PAH as an intermediate phenotype between
normal and resting PAH assessed by cardiopulmonary
exercise and hemodynamic end points in symptomatic
non-SSc patients (18). Furthermore, a recent report
described an association between exercise hemodynam-
ics (mPAP) and exercise capacity (6-minute walking
distance and peak maximum V̇O2 [V̇O2max]) in an SSc
cohort without resting PAH (5). Additional investigation
is needed to determine the appropriate indicators of
maximum effort and the prognostic value of VO2max and
6-minute walking distance in SSc patients with ePH.
In our study, 3 patients (25%) developed resting
PH (mPAP 25 mm Hg) despite receiving ambrisentan.
Surprisingly, only 1 of the 3 patients had a decline in
6-minute walking distance accompanied by a worsening
functional class. The remaining 2 patients had improved
exercise capacity and unchanged functional class, sug-
gesting a possible discordance between hemodynamics
(mPAP) and 6-minute walking distance.
Interestingly, 2 of the 3 patients who progressed
to develop resting PH had an FVC of 60%, whereas
the rest of the cohort had an FVC of 60%. Patients
with an FVC of 60% associated with significant inter-
stitial lung disease are excluded from WHO class I, and
the associated pulmonary vasculopathy is often consid-
ered to be a manifestation of the underlying interstitial
lung disease and/or hypoxia (15). Nevertheless, SSc-
associated PH with pulmonary fibrosis also portends a
poorer prognosis than isolated SSc-associated PAH (1).
We suggest that this specific population should be
evaluated in a longitudinal manner.
The Dana Point guidelines recommended that
the exercise criterion of an mPAP value of 30 mm Hg
to designate ePH should be reassessed, given both the
marked age dependency of the normal mPAP threshold
on exercise and the paucity of robust data supporting its
clinical relevance (15,19). In addition, these guidelines
highlighted the importance of close monitoring of pa-
tients with a resting mPAP of 21–24 mm Hg (15). In our
study, the mean age was 47.6 years, and 9 of 12 patients
had a resting mPAP of 21–24 mm Hg.
Common adverse events seen during our clinical
trial have been previously reported in clinical trials of
ambrisentan, and they were anticipated. Adverse events
included lower extremity edema, nasal congestion, and
upper respiratory symptoms. The majority of these
adverse events were managed by either decreasing the
dose of ambrisentan or temporarily discontinuing am-
brisentan. Persistent lower extremity edema was typi-
cally managed with the addition of a daily oral loop
diuretic.
There were a few adverse events that were sur-
prising. One patient, who had minimal fibrosis at base-
line, developed a new bronchoalveolar carcinoma, which
was detected on a high-resolution CT chest scan at week
24. This was judged not to be related to the study drug.
Currently, there are no reports of carcinogenesis in
humans attributable to ambrisentan (according to the
package label). Ambrisentan-related carcinogenicity has
been described in studies of male rats receiving 8–140
times the maximum recommended dose (in mg/m2) for
humans (package label).
Although our results are promising, they are
restricted by the small number of patients, the single-
center design of the trial, the absence of a placebo
group, inclusion of patients with pulmonary fibrosis, and
the absence of simultaneous cardiopulmonary exercise
testing. Our data indicate that SSc patients with normal
resting pulmonary hemodynamics may have abnormal
pulmonary hemodynamics during exercise. We there-
fore view this study as generating a hypothesis and as a
basis for a larger placebo-controlled trial.
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